September 2025

Invex Therapeutics Ltd has had its trading suspension lifted following the announcement of a material acquisition, signaling a pivotal moment for the biotech company.

Invex Therapeutics reveals the collapse of confidential acquisition negotiations following shareholder unrest and potential board changes, clarifying recent unusual trading activity.

Invex Therapeutics has discontinued exclusive negotiations to acquire a rare neurological disease company due to board instability triggered by a shareholder requisition notice. Despite this setback, the company remains committed to diversifying its neurological treatment portfolio.

Hydrix Limited delays its FY25 financial statements due to a pending independent valuation of its Wavewise Analytics shareholding, triggering an automatic trading suspension from 1 October 2025.

VEEM Ltd has secured $14 million through a placement to fuel its expansion in defence manufacturing, including a landmark US$33 million licence agreement with Northrop Grumman. The company is poised to accelerate revenue in the second half of FY26 as it deepens ties with major US defence contractors.

VEEM Limited has completed a $14 million placement to accelerate its growth in the defence sector, highlighted by a new 9-year manufacturing licence agreement with Northrop Grumman valued initially at US$33 million. This positions VEEM alongside major US defence contractors and signals a significant step into the expanding submarine and naval supply chains.

Starpharma has entered a strategic research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset using its proprietary dendrimer technology, unlocking potential milestone payments of up to AUD $89 million.

Spirit Technology Solutions forecasts strong FY26 growth with revenue surpassing $114 million and underlying EBITDA rising between 14% and 23%. The company signals ongoing expansion through organic and potential inorganic avenues.

Washington H. Soul Pattinson and Brickworks Limited have completed their long-anticipated merger, unveiling standalone FY25 results that highlight robust revenue growth and a significant profit turnaround. The combined entity, trading under the Soul Patts ticker SOL, is poised for diversified growth across property, building products, and investment portfolios.

Hillgrove Resources has secured $28 million through a two-tranche placement to accelerate copper production growth at its Kanmantoo mine, focusing on the Emily Star and Nugent projects.

Dotz Nano has secured its first commercial order for its innovative Amine-Modified Polymer CO2 sorbent from a leading automotive innovation hub, marking a key step toward commercial deployment in sustainable aviation fuel production.

Riversgold has partnered with MEGA Resources to fully fund and operate mining at its Northern Zone Gold Project near Kalgoorlie, sharing profits equally and aiming to commence mining in early 2026.

Sky Metals has reported upgraded assay results from its Tallebung Tin Project in NSW, revealing multiple new shallow, high-grade tin and silver mineralisation zones. A major drilling campaign of over 100 holes is poised to begin imminently, aiming to expand and upgrade the resource.

Aguia Resources has announced a one-for-ten entitlement issue to raise up to $4 million, including free attaching options, aimed at advancing its Santa Barbara Gold Project and supporting working capital.

Legacy Minerals has secured NSW Government approvals to drill new high-grade silver and copper-gold targets at its Mt Carrington Project, initiating a key phase of exploration that could expand its 1.2Moz gold equivalent resource.

MC Mining’s FY2025 results reveal a sharp increase in losses driven by impairments and lower coal sales, while a strategic investment by Kinetic Development Group advances its flagship Makhado Project.

360 Capital Mortgage REIT (ASX – TCF) has announced an off-market equal access buy-back of up to 5% of its units, offering eligible unitholders a chance to sell at a price linked to net tangible asset backing plus distributions. The buy-back opens on 8 October 2025 and closes on 27 October 2025.

Lode Resources has reported promising early exploration results at its Montezuma Silver & Antimony Project in Tasmania, revealing high-grade assays and expanding its land holdings in a critical minerals hotspot.

Nova Eye Medical has gained regulatory approval for its iTrack Advance glaucoma device in China, setting the stage for significant market expansion and sales growth from late fiscal 2026.

Tesoro Gold has raised A$34 million through a strategic placement to fund critical development stages of its El Zorro Gold Project in Chile, aiming for a final investment decision.

Larvotto Resources has identified compelling new drill targets at its Kiarra Prospect within the Hillgrove Antimony-Gold Project, following a successful induced polarisation and resistivity survey. The findings suggest potential extensions of historic mineralisation, setting the stage for upcoming drilling campaigns.

Toubani Resources has reported promising drill results extending gold mineralisation beyond the current Kobada resource estimate, highlighting potential for resource growth both near surface and at depth.

Papyrus Australia has appointed Daniel Schmidt as CEO and secured a $250k government grant alongside a binding agreement to produce biodegradable mining products, marking a decisive shift from R&D to commercial operations.

Sprintex Limited has raised $1.5 million through a strategic placement to advance its ammonia-reduction technology in Europe, supported by pending orders worth €9.3 million. The funding underscores growing investor confidence amid tightening environmental regulations.